FibroBiologics’ CYPS317 Spheroids Cut Psoriasis Severity and Prevent Relapse in Mice
FibroBiologics presented preclinical data showing its CYPS317 human dermal fibroblast spheroids reduced psoriasis severity, prevented relapse, and avoided innate immune activation in mouse models. Booster dosing sustained efficacy, lowered PASI scores and prevented splenomegaly, highlighting durable immunomodulation via targeted cytokine regulation.
1. Preclinical Efficacy in Psoriasis Models
FibroBiologics' CYPS317 spheroids reduced disease severity and PASI scores in imiquimod-induced and chronic-relapse mouse models, sustained therapeutic effects with booster dosing, and prevented hallmark epidermal thickening and immune cell infiltration.
2. Favorable Safety and Immunomodulation Mechanism
Spheroid delivery avoided systemic innate immune activation seen with single-cell fibroblasts, prevented splenomegaly, normalized monocyte-to-lymphocyte ratios, and demonstrated targeted cytokine regulation without broad immune suppression.
3. Differentiated Pipeline and Patent Strength
The CYPS317 program builds on FibroBiologics' clinical-stage pipeline and over 270 issued or pending patents, reinforcing its strategic focus on fibroblast-based therapies for chronic inflammatory diseases.